ArticleBioconjugate chemistry
Surface engineering of quantum dots for in vivo vascular imaging.
Article in Bioconjugate chemistry. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 107 citations in OpenAlex.
- Advancements in nanomaterials for the treatment and management of vascular surgeries: from drug delivery to biomedical implants.Frontiers in bioengineering and biotechnology · 2026Review
- Novel Optical Imaging Probe for the Targeted Visualization of NLRP3 Inflammasomes in Living Retina.Journal of medicinal chemistry · 2025Article
- In Vitro Tracking of Human Umbilical Vein Endothelial Cells Using Ultra-Sensitive Quantum Dot-Embedded Silica Nanoparticles.International journal of molecular sciences · 2023Article
- Vascular Nanomedicine: Current Status, Opportunities, and Challenges.Seminars in thrombosis and hemostasis · 2020Review
- Recording the wild lives of immune cells.Science immunology · 2018Review
- Cytotoxicity of InP/ZnS Quantum Dots With Different Surface Functional Groups Toward Two Lung-Derived Cell Lines.Frontiers in pharmacology · 2018Article
- Recent Advances in Retinal Stem Cell Therapy.Current molecular biology reports · 2017Article
- In vivo biodistribution and behavior of CdTe/ZnS quantum dots.International journal of nanomedicine · 2017Article
- Nanomedicine in the application of uveal melanoma.International journal of ophthalmology · 2016Review
- Cytocompatibility of direct water synthesized cadmium selenide quantum dots in colo-205 cells.Journal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology · 2015Article
- Deglycosylation of mAb by EndoS for improved molecular imaging.Molecular imaging and biology · 2015Article
- Intravital microscopic methods to evaluate anti-inflammatory effects and signaling mechanisms evoked by hydrogen sulfide.Methods in enzymology · 2015Article
- Drug and gene delivery to the back of the eye: from bench to bedside.Investigative ophthalmology & visual science · 2014Review
- Dual-modal magnetic resonance and fluorescence imaging of atherosclerotic plaques in vivo using VCAM-1 targeted tobacco mosaic virus.Nano letters · 2014Article
- Article
- NANOMATERIALS FOR PROTEIN MEDIATED THERAPY AND DELIVERY.Nano LIFE · 2013Article
- Quantum dot-based nanoprobes for in vivo targeted imaging.Current molecular medicine · 2013Review
- Reduction of nanoparticle avidity enhances the selectivity of vascular targeting and PET detection of pulmonary inflammation.ACS nano · 2013Article
- Molecular imaging of retinal disease.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2013Review
- Targeted Nanocarriers for Imaging and Therapy of Vascular Inflammation.Current opinion in colloid & interface science · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Quantum dot-antibody bioconjugates (QD-mAb) were synthesized incorporating PEG cross-linkers and Fc-shielding mAb fragments to increase in vivo circulation times and targeting efficiency. Microscopy of endothelial cell cultures incubated with QD-mAb directed against cell adhesion molecules (CAMs), when shielded to reduce Fc-mediated interactions, were more specific for their molecular targets. In vitro flow cytometry indicated that surface engineered QD-mAb labeled leukocyte subsets with minimal Fc-mediated binding. Nontargeted QD-mAb nanoparticles with Fc-blockade featured 64% (endothelial cells) and 53% (leukocytes) lower nonspecific binding than non-Fc-blocked nanoparticles. Spectrally distinct QD-mAb targeted to the cell adhesion molecules (CAMs) PECAM-1, ICAM-1, and VCAM-1 on the retinal endothelium in a rat model of diabetes were imaged in vivo using fluorescence angiography. Endogenously labeled circulating and adherent leukocyte subsets were imaged in rat models of diabetes and uveitis using QD-mAb targeted to RP-1 and CD45. Diabetic rats exhibited increased fluorescence in the retinal vasculature from QD bioconjugates to ICAM-1 and VCAM-1 but not PECAM-1. Both animal models exhibited leukocyte rolling and leukostasis in capillaries. Examination of retinal whole mounts prepared after in vivo imaging confirmed the fluorescence patterns seen in vivo. Comparison of the timecourse of retinal fluorescence from Fc-shielded and non-Fc-shielded bioconjugates indicated nonspecific uptake and increased clearance of the non-Fc-shielded QD-mAb. This combination of QD surface design elements offers a promising new in vivo approach to specifically label vascular cells and biomolecules of interest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.